546 related articles for article (PubMed ID: 27852327)
1. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic localization of alteration/deficiency in activation 3 (ADA3) predicts poor clinical outcome in breast cancer patients.
Mirza S; Rakha EA; Alshareeda A; Mohibi S; Zhao X; Katafiasz BJ; Wang J; Gurumurthy CB; Bele A; Ellis IO; Green AR; Band H; Band V
Breast Cancer Res Treat; 2013 Feb; 137(3):721-31. PubMed ID: 23288344
[TBL] [Abstract][Full Text] [Related]
3. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
4. TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer.
Seksenyan A; Kadavallore A; Walts AE; de la Torre B; Berel D; Strom SP; Aliahmad P; Funari VA; Kaye J
BMC Cancer; 2015 Jan; 15():22. PubMed ID: 25632947
[TBL] [Abstract][Full Text] [Related]
5. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Loo LWM; Jia W; Obata Y; Yu H
Breast Cancer Res Treat; 2018 Sep; 171(2):261-271. PubMed ID: 29845475
[TBL] [Abstract][Full Text] [Related]
6. Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation.
Germaniuk-Kurowska A; Nag A; Zhao X; Dimri M; Band H; Band V
Cancer Res; 2007 Dec; 67(24):11789-97. PubMed ID: 18089809
[TBL] [Abstract][Full Text] [Related]
7. Cytoplasmic Skp2 expression is associated with p-Akt1 and predicts poor prognosis in human breast carcinomas.
Liu J; Wei XL; Huang WH; Chen CF; Bai JW; Zhang GJ
PLoS One; 2012; 7(12):e52675. PubMed ID: 23300741
[TBL] [Abstract][Full Text] [Related]
8. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers.
Ahlin C; Lundgren C; Embretsén-Varro E; Jirström K; Blomqvist C; Fjällskog M-
Breast Cancer Res Treat; 2017 Aug; 164(3):667-678. PubMed ID: 28528450
[TBL] [Abstract][Full Text] [Related]
9. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
10. RECK is not an independent prognostic marker for breast cancer.
Gomes LR; Fujita A; Mott JD; Soares FA; Labriola L; Sogayar MC
BMC Cancer; 2015 Oct; 15():660. PubMed ID: 26449734
[TBL] [Abstract][Full Text] [Related]
11. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
[TBL] [Abstract][Full Text] [Related]
12. Expression of the CCAAT/enhancer-binding proteins C/EBPalpha, C/EBPbeta and C/EBPdelta in breast cancer: correlations with clinicopathologic parameters and cell-cycle regulatory proteins.
Milde-Langosch K; Löning T; Bamberger AM
Breast Cancer Res Treat; 2003 May; 79(2):175-85. PubMed ID: 12825852
[TBL] [Abstract][Full Text] [Related]
13. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.
Nilsson EM; Brokken LJ; Narvi E; Kallio MJ; Härkönen PL
Mol Cell Endocrinol; 2012 Jul; 358(1):104-15. PubMed ID: 22465097
[TBL] [Abstract][Full Text] [Related]
14. Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.
Yuan SS; Hou MF; Hsieh YC; Huang CY; Lee YC; Chen YJ; Lo S
J Natl Cancer Inst; 2012 Oct; 104(19):1485-502. PubMed ID: 22914783
[TBL] [Abstract][Full Text] [Related]
15. TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesterone.
Gizard F; Robillard R; Gross B; Barbier O; Révillion F; Peyrat JP; Torpier G; Hum DW; Staels B
Mol Cell Biol; 2006 Oct; 26(20):7632-44. PubMed ID: 17015480
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.
Savva C; De Souza K; Ali R; Rakha EA; Green AR; Madhusudan S
Breast Cancer Res Treat; 2019 May; 175(1):105-115. PubMed ID: 30746633
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.
Arora A; Parvathaneni S; Aleskandarany MA; Agarwal D; Ali R; Abdel-Fatah T; Green AR; Ball GR; Rakha EA; Ellis IO; Sharma S; Madhusudan S
Mol Cancer Ther; 2017 Jan; 16(1):239-250. PubMed ID: 27837030
[TBL] [Abstract][Full Text] [Related]
18. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients.
Ibusuki M; Yamamoto Y; Shinriki S; Ando Y; Iwase H
Cancer Sci; 2011 Feb; 102(2):439-45. PubMed ID: 21134077
[TBL] [Abstract][Full Text] [Related]
19. Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers.
Ding J; Kuo ML; Su L; Xue L; Luh F; Zhang H; Wang J; Lin TG; Zhang K; Chu P; Zheng S; Liu X; Yen Y
Carcinogenesis; 2017 May; 38(5):519-531. PubMed ID: 28379297
[TBL] [Abstract][Full Text] [Related]
20. Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.
Filipits M; Dafni U; Gnant M; Polydoropoulou V; Hills M; Kiermaier A; de Azambuja E; Larsimont D; Rojo F; Viale G; Toi M; Harbeck N; Prichard KI; Gelber RD; Dinh P; Zardavas D; Leyland-Jones B; Piccart-Gebhart MJ; Dowsett M;
Clin Cancer Res; 2018 Jul; 24(13):3079-3086. PubMed ID: 29530933
[No Abstract] [Full Text] [Related]
[Next] [New Search]
